These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30910285)

  • 1. Corrigendum to "Dexamethasone-eluting stents for the prevention of in-stent restenosis: Evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients" [Int. J. Cardiol. 124 (2008) 166-171].
    van der Hoeven BL; Pires NMM; Warda HM; Putter H; Quax PHA; Schalij MJ; Jukema JW
    Int J Cardiol; 2019 Jul; 287():211. PubMed ID: 30910285
    [No Abstract]   [Full Text] [Related]  

  • 2. Dexamethasone-eluting stents for the prevention of in-stent restenosis: evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients.
    van der Hoeven BL; Pires NM; Warda HM; Putter H; Quax PH; Schalij MJ; Jukema JW
    Int J Cardiol; 2008 Feb; 124(2):166-71. PubMed ID: 17408773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis.
    Liu X; De Scheerder I; Desmet W
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):653-60. PubMed ID: 15350167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary artery stent fracture with aneurysm formation and in-stent restenosis.
    Manola S; Pintarić H; Pavlović N; Stambuk K
    Int J Cardiol; 2010 Apr; 140(2):e36-9. PubMed ID: 19108918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
    Sabaté M; Jiménez-Quevedo P; Angiolillo DJ; Gómez-Hospital JA; Alfonso F; Hernández-Antolín R; Goicolea J; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Circulation; 2005 Oct; 112(14):2175-83. PubMed ID: 16203930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study to compare bioactive titanium stents and everolimus-eluting stents in diabetic patients (TITANIC XV): 1-year results.
    López-Mínguez JR; Nogales-Asensio JM; Doncel-Vecino LJ; Merchán-Herrera A; Pomar-Domingo F; Martínez-Romero P; Fernández-Díaz JA; Valdesuso-Aguilar R; Moreu-Burgos J; Díaz-Fernández J;
    Rev Esp Cardiol (Engl Ed); 2014 Jul; 67(7):522-30. PubMed ID: 24952391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus-eluting stents for the prevention of restenosis in a worst-case scenario of diffuse and recurrent in-stent restenosis.
    Werner GS; Emig U; Krack A; Schwarz G; Figulla HR
    Catheter Cardiovasc Interv; 2004 Nov; 63(3):259-64. PubMed ID: 15505841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
    Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
    JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
    Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
    Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials.
    Byrne RA; Cassese S; Windisch T; King LA; Joner M; Tada T; Mehilli J; Pache J; Kastrati A
    EuroIntervention; 2013 Nov; 9(7):797-802. PubMed ID: 23687095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
    Moussa I; Leon MB; Baim DS; O'Neill WW; Popma JJ; Buchbinder M; Midwall J; Simonton CA; Keim E; Wang P; Kuntz RE; Moses JW
    Circulation; 2004 May; 109(19):2273-8. PubMed ID: 15123524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
    Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
    J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M
    Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study.
    Han SH; Ahn TH; Kang WC; Oh KJ; Chung WJ; Shin MS; Koh KK; Choi IS; Shin EK
    Am Heart J; 2006 Nov; 152(5):887.e1-7. PubMed ID: 17070150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results after drug-eluting stent implantation in diabetic patients according to diabetic treatment.
    Voudris V; Karyofillis P; Thomopoulou S; Doulaptsis C; Manginas A; Pavlides G; Cokkinos DV
    Hellenic J Cardiol; 2011; 52(1):15-22. PubMed ID: 21292603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Insulin Resistance on Neointimal Tissue Proliferation after 2nd-Generation Drug-Eluting Stent Implantation.
    Komatsu T; Yaguchi I; Komatsu S; Nakahara S; Kobayashi S; Sakai Y; Taguchi I
    Tex Heart Inst J; 2015 Aug; 42(4):327-32. PubMed ID: 26413014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid-eluting stents in patients with acute coronary syndromes. Angiographic results of DESIRE: Dexamethasone-Eluting Stent Italian REgistry.
    Pesarini G; Ferrero V; Tomai F; Paloscia L; De Cesare N; Tamburino C; Piscione F; Vassanelli F; Ribichini F;
    J Invasive Cardiol; 2009 Mar; 21(3):86-91. PubMed ID: 19258636
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.